J
Julie M. Vose
Researcher at University of Nebraska Medical Center
Publications - 569
Citations - 51589
Julie M. Vose is an academic researcher from University of Nebraska Medical Center. The author has contributed to research in topics: Transplantation & Lymphoma. The author has an hindex of 97, co-authored 541 publications receiving 46915 citations. Previous affiliations of Julie M. Vose include Memorial Hospital of South Bend.
Papers
More filters
Journal ArticleDOI
Split dose ATG strategy prevents grade III-IV acute GVHD and is associated with immune surrogates of GVL
Zaid S Al-Kadhimi,Samuel J. Pirruccello,Zartash Gul,Lori J Maness-Harris,Vijaya Raj Bhatt,Krishna Gundabolu,Jane Yuan,Matthew A. Lunning,Gregory Bociek,Christopher D'Angelo,Avyakta Kallam,James O. Armitage,Khansaa Fadhil Abdullah,Angela Hunter,Sarah Mccaslin,Elizabeth Lyden,Lynnette Smith,Michael Callahan,Kathryn E. Cole,Steven Hinrichs,James E. Talmadge,Julie M. Vose +21 more
TL;DR: A split dose ATG strategy resulted in complete prevention of grade III-IV aGVHD, relatively low cGV HD, NRM, and high GRFS and was associated with enhanced immune reconstitution, and relapse predictive phenotypes.
Journal ArticleDOI
Thirty-Five Year Follow-up Analysis of Follicular Lymphoma Patients Treated through the Nebraska Lymphoma Study Group: Prognostic Factor Analysis and Outcomes
Amulya Yellala,Elizabeth Lyden,Heather Nutsch,Avyakta Kallam,Kai Fu,Timothy C. Greiner,Philip J. Bierman,Matthew A. Lunning,R. Gregory Bociek,James O. Armitage,Julie M. Vose +10 more
TL;DR: This study evaluated a large patient cohort with FL treated over a 35 year period for progression free survival (PFS), overall survival (OS) based on FLIPI score, tumor grade, and treatment regimen and also looked at causes of late failures.
Journal ArticleDOI
Peripheral t-cell lymphoma-a brief review
TL;DR: Peripheral T-Cell Lymphoma–A Brief Review Julie M. Vose, Dennis D. Sanger, Philip J. Bierman & James O. Armitage.
Journal ArticleDOI
Outcomes of Patients with Limited-Stage Aggressive Large B-Cell Lymphoma with MYC Rearrangement with and without BCL2 and/or BCL6 Rearrangements: A Retrospective Analysis from 15 US Academic Centers
Shalin Kothari,Shaoying Li,L. Jeffrey Medeiros,Emily C. Ayers,Daniel J. Landsburg,David A. Bond,Kami J. Maddocks,Anshu Giri,Brian T. Hess,Luu Q. Pham,Ranjana H. Advani,Yang Liu,Stefan K. Barta,Julie M. Vose,Michael C. Churnetski,Jonathon B. Cohen,Madelyn Burkart,Reem Karmali,Joanna C. Zurko,Amitkumar Mehta,Adam J. Olszewski,Sarah S Lee,Brian T. Hill,Timothy F. Burns,Frederick Lansigan,Emma Rabinovich,David Peace,Adrienne Groman,Kris Attwood,Francisco J. Hernandez-Ilizaliturri,Pallawi Torka +30 more
TL;DR: Differences in overall response rate (ORR), complete remission (CR) rate, 2-year progression-free survival (PFS) and overall survival (OS) were compared in patients with limited stage (LS) aggressive large B-cell lymphoma and in pts treated with R-CHOP or more intensive immuno-chemotherapy (IIC) with or without IFRT.
Journal ArticleDOI
Combination of Ublituximab, TGR-1202, and Bendamustine Demonstrates Significant Activity in Patients with Advanced DLBCL and Follicular Lymphoma
Matthew A. Lunning,Philip J. Bierman,R. Gregory Bociek,Marshall T. Schreeder,Susan Blumel,Kathy Cutter,Emily K. Pauli,Peter Sportelli,Hari P. Miskin,Michael S. Weiss,Julie M. Vose +10 more
TL;DR: The combination of UTX, TGR-1202, and bendamustine has exhibited manageable toxicity with significant activity (100% ORR) including a 50% CR rate in pts with advanced DLBCL and FL.